Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Mr. D.J. Ferguson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mr. D.J. Ferguson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The New Chemist’s Podcasting Group: The Path to KOLs — Interview with Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI — Co-Founder, United Theranostics

45:02
 
Share
 

Manage episode 499461513 series 2970140
Content provided by Mr. D.J. Ferguson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mr. D.J. Ferguson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

The New Chemist’s Podcasting Group: The Path to KOLs — Interview with Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI — Co-Founder, United Theranostics

---

🎙️ In this episode of The Path to KOLs, Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI—co-founder of United Theranostics—explains how his team is moving Pluvicto from single mega-centers into safe, consistent community clinics. We dig into the toughest regulatory and logistical hurdles, the playbook for dosing accuracy, imaging quality, and safety, and how clinics are designed for a compassionate, family-centered patient journey with real-world feedback loops.

Dr. Morris also shares how United Theranostics trains local technologists, pharmacists, and nurses, mentors future KOLs, and maps a path to coverage across all 50 states. Looking ahead, we discuss what’s beyond Pluvicto—including actinium-225 PSMA approaches—and how telehealth, remote monitoring, and AI are improving patient selection, follow-up, and outcomes.

About the guest: Dr. Morris is a physician-scientist in nuclear medicine, diagnostic radiology, and clinical informatics; Medical Director in Glen Burnie, MD; adjunct faculty at the University of Miami and University of Maryland; and a principal investigator on multiple FDA clinical trials in prostate cancer and neuroendocrine tumors.

Subscribe for actionable insights at the intersection of innovation, operations, and patient-centered care.

Music by Dmitrii Kolesnikov from Pixabay

Please note: The views of this podcast reflect those of my guest(s) and I, and do not constitute in any way medical advice or consultation. Please see a board and state certified medical professional for advice, consultation and suggestions.

  continue reading

323 episodes

Artwork
iconShare
 
Manage episode 499461513 series 2970140
Content provided by Mr. D.J. Ferguson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mr. D.J. Ferguson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

The New Chemist’s Podcasting Group: The Path to KOLs — Interview with Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI — Co-Founder, United Theranostics

---

🎙️ In this episode of The Path to KOLs, Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI—co-founder of United Theranostics—explains how his team is moving Pluvicto from single mega-centers into safe, consistent community clinics. We dig into the toughest regulatory and logistical hurdles, the playbook for dosing accuracy, imaging quality, and safety, and how clinics are designed for a compassionate, family-centered patient journey with real-world feedback loops.

Dr. Morris also shares how United Theranostics trains local technologists, pharmacists, and nurses, mentors future KOLs, and maps a path to coverage across all 50 states. Looking ahead, we discuss what’s beyond Pluvicto—including actinium-225 PSMA approaches—and how telehealth, remote monitoring, and AI are improving patient selection, follow-up, and outcomes.

About the guest: Dr. Morris is a physician-scientist in nuclear medicine, diagnostic radiology, and clinical informatics; Medical Director in Glen Burnie, MD; adjunct faculty at the University of Miami and University of Maryland; and a principal investigator on multiple FDA clinical trials in prostate cancer and neuroendocrine tumors.

Subscribe for actionable insights at the intersection of innovation, operations, and patient-centered care.

Music by Dmitrii Kolesnikov from Pixabay

Please note: The views of this podcast reflect those of my guest(s) and I, and do not constitute in any way medical advice or consultation. Please see a board and state certified medical professional for advice, consultation and suggestions.

  continue reading

323 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play